Ubrogepant

CAS: 1374248-77-7

Ref. 3D-FU165699

Produktinformation

• Name: Ubrogepant
• Synonyme: Ubrelvy, Spiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide, 1′,2′,5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxo-, (3′S)-, (3′S)-1′,2′,5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxospiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide, MK 1602

Beschreibung

Ubrogepant is a small-molecule drug that is used to treat migraine. It inhibits the activity of a receptor called CGRP, which is associated with the development of migraine headaches. Ubrogepant has been shown to be effective in treating chronic cough and has also been found to be safe for long-term use. The drug does not have significant toxicity or major side effects. Ubrogepant may increase the risk of bleeding and gastrointestinal disorders when used with nonsteroidal anti-inflammatory drugs (NSAIDs).

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 549.54 g/mol
• Formel: C₂₉H₂₆F₃N₅O₃
• Reinheit: Min. 95%